Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02124148 · ClinicalTrials.gov registry record · Phase 1

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

A Phase 1 study of Breast Cancer and Colorectal Neoplasms, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
167
Enrollment target
5
Study locations

NCT02124148 is a Phase 1 study of Breast Cancer and Colorectal Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 167 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02124148, a Phase 1 study of Breast Cancer and Colorectal Neoplasms, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
167 participants
Enrollment target
5
Study locations

Study Summary

The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.

Conditions Studied

Breast Cancer Colorectal Neoplasms Neoplasm Metastasis

Interventions

  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG G-CSF
  • DRUG Cetuximab
  • DRUG Prexasertib

Study Locations (5)

Tennessee

  • Sarah Cannon Research Institute SCRI - Nashville
  • Tennessee Oncology PLLC - Nashville

Florida

  • Florida Cancer Specialists - Sarasota

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2014-06-18
Est. Completion 2020-02-13
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02124148

The ClinicalTrials.gov registry entry for NCT02124148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.

NCT02124148 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, Florida, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT02124148 about?

NCT02124148 is a clinical study titled "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer". The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple part...

What is the current status of trial NCT02124148?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 167 participants. The study started on 2014-06-18. Estimated completion is 2020-02-13.

What conditions does trial NCT02124148 study?

This clinical trial studies the following conditions: Breast Cancer, Colorectal Neoplasms, Neoplasm Metastasis.

What interventions are being tested in trial NCT02124148?

The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), G-CSF (DRUG), Cetuximab (DRUG), Prexasertib (DRUG).

Who is sponsoring clinical trial NCT02124148?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02124148 being conducted?

This trial has 5 study locations across Florida, Oklahoma, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Colorectal Neoplasms

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.